We demonstrate the presence and hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors (CRF-R) in C57BL/6 mouse skin. To correlate this with a physiological, developmentally controlled tissue remodeling process, we have analyzed CRF and CRF-R expression during defined stages of the murine hair cycle with its rhythmic changes between growth (anagen), regression (catagen), and resting (telogen). Using reversed-phase HPLC combined with two independent anti-CRF radioimmunoassays, we have identified CRF in murine skin. Maximal CRF levels were found in anagen III-IV skin, and minimal values were detected in catagen and telogen skin. By immunofluorescence, maximal CRF immunoreactivity (CRF-IR) was seen in the basal epidermis, nerve bundles of skin, the outer root sheath and matrix region of anagen IV-VI follicles, and in defined sections of their perifollicular neural network, whereas catagen and telogen skin displayed minimal CRF-IR. Using quantitative autoradiography and 125 I-CRF as a tracer, high-affinity binding sites for CRF were detected in murine skin. The highest density of specific binding sites was detected in the panniculus carnosus, the epidermis, and the hair follicle. CRF-R type 1 (CRF-R1) IR was detected by immunohistology mainly in the outer root sheath, hair matrix, and dermal papilla of anagen VI follicles, as well as in the inner and outer root sheaths of early catagen follicles. CRF-R1 expression was also hair cycle dependent. Therefore, in normal murine skin, the CRF-CRF-R signaling system may operate as an additional neuroendocrine pathway regulating skin functions, possibly in the context of cutaneous stress responses.-Roloff, B., Fechner, K., Slominski, A., Furkert, J, Botchkarev, V. A., Bulfone-Paus, S., Zipper, J., Krause, E., Paus, R. Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. FASEB J. 12, 287-297 (1998) 
I-CRF as a tracer, high-affinity binding sites for CRF were detected in murine skin. The highest density of specific binding sites was detected in the panniculus carnosus, the epidermis, and the hair follicle. CRF-R type 1 (CRF-R1) IR was detected by immunohistology mainly in the outer root sheath, hair matrix, and dermal papilla of anagen VI follicles, as well as in the inner and outer root sheaths of early catagen follicles. CRF-R1 expression was also hair cycle dependent. Therefore, in normal murine skin, the CRF-CRF-R signaling system may operate as an additional neuroendocrine pathway regulating skin functions, possibly in the context of cutaneous stress responses.-Roloff, B., Fechner, K., Slominski, A., Furkert, J, Botchkarev, V. A., Bulfone-Paus, S., Zipper, J., Krause, E., Paus, R. Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. FASEB J. 12, 287-297 (1998) Key Words: stress · hair growth · C57BL/6 mouse CORTICOTROPIN-RELEASING FACTOR (CRF), 2 CRF receptors (CRF-R), and proopiomelanocortin (POMC) are components of the main adaptive response to systemic stress (1) (2) (3) (4) . CRF, a main regulator of pituitary POMC peptide production, is a 41-amino acid peptide synthetized by cleavage from a large 191-amino acid precursor (2) . The CRF gene has two exons, separated by an intron whose prohormone sequence is located in exon 2 (5) . CRF exerts its bioregulatory function via activation of CRF-R. Two distinct gene subfamilies encoding CRF-R were cloned, which share high sequence homology and belong to the seven-transmembrane receptor protein family, coupled to the Gs signaling protein (6) (7) (8) (9) . In addition to the brain and pituitary (6, 9) , the CRF-R1 (CRF-R type 1) gene is also transcribed in skin (10, 11) , although its cutaneous site of expression is unknown. CRF-R2 includes the CRF-R2a, found predominantly in the brain, and CRF-R2b, which is expressed in heart and skeletal muscle (7, 8) .
It has recently been proposed that mammalian skin may contain an equivalent of the 'hypothalamic-pituitary axis' that regulates skin responses to stress (4) . This hypothesis is supported by the fact that the skin, which is a recognized target for melanocyte-stimulating hormone (MSH) and adrenocorticotropin (ACTH) bioregulation, expresses the POMC gene and produces POMC peptides like MSH, ACTH, and b-endorphin (cf. refs 3, 12) . In addition, human skin can express CRF and CRF-R1 mRNA (10) . To further explore this hypothesis in a model system for developmentally controlled epithelial-mesenchymal-neuroectodermal interaction, we studied CRF and CRF-R expression during the depilation-induced hair cycle in the C57BL/6 mouse (13) (14) (15) (16) .
The hair cycle is characterized by three rhythmically interchanging stages: resting (telogen), growth (anagen), and regression (catagen) (14, 17) . In mice, hair follicle cycling is highly synchronized and is associated with profound changes in the architecture and physiology of all skin compartments, including skin pigmentary, endocrine, and immune systems (11, (14) (15) (16) (17) (18) (19) (20) (21) . Murine skin transcription and translation of the POMC gene, accumulation of POMC-derived neuropeptides like b-endorphin, and expression of the receptors for some POMC-derived peptides are all hair cycle dependent (11, 20, 22) .
In this study, we have further explored the hypothesis that CRF and functional CRF-R proteins are expressed in mammalian skin as part of a cutaneous equivalent of a hypothalamus-pituitary axis (4). Therefore, cutaneous CRF and CRF-R expression was examined on the molecular and cellular levels during the induced hair cycle in C57BL/6 mice.
MATERIALS AND METHODS

Materials
Ovine (o) CRF, human (h) CRF, hCRF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] were synthesized by solid-phase methodology (23, 24) and were kindly provided by Dr. M. Beyermann and Dr. J. Eichler (Institute of Molecular Pharmacology, Berlin). hCRF(Ox) (methionine sulfoxide analog of hCRF) was synthesized as described (23, 24 ]-hCRF (74TBq/mmol) was purchased from Amersham Buchler GmbH (Braunschweig, Germany). Bovine serum albumin (BSA) was from Gibco BRL Life Technologies (Paisley, U.K.), Triton X-100 was from Ferak (Berlin, Germany), and sheep anti-rabbit antibody was provided by Pharmacia Biosystems GmbH (Freiburg, Germany). Bacitracin and aprotinin were from Merck (Darmstadt, Germany) and ethylene glycol bis(2-aminoethylether)-N,N,N,N-tetraaceticacid (EGTA) was from Sigma (St. Louis, Mo.).
Animals and skin collection
Syngeneic, female C57/BL/6 mice (6 to 9 wk old) weighing 15-20 g (Charles River, Sulzfeld, Germany, or Taconic, N.Y.) were housed in community cages under a 12 h light/darkness cycle in the Virchow Hospital Animal Facilities, Berlin, or in the Albany Medical College Animal Facilities, Albany, N.Y. Mice were fed mouse chow and water ad libitum. Active hair growth (anagen) was induced in the back skin of mice in the telogen phase by depilation, as described before (13) . All key hair cycle stages (14) were studied and at least five mice were used per time point. The animals were killed by cervical dislocation under overdose anesthesia; the skin was harvested at the level of subcutis and stored at 070ЊC until further use.
For receptor autoradiography and immunohistology, skin was harvested in parallel to the vertebral line, and a special cryoembedding technique was used to allow longitudinal sections to be cut through the entire hair follicle (19) .
Peptide extraction
Peptide extraction was performed independently, in two different laboratories, using three distinct extraction protocols.
Extraction protocol #1
The harvested skin was immediately frozen in liquid nitrogen, pulverized in a mortar, and stored at 070ЊC until use. To prevent skin gel formation in an acidic environment (22) , acetonitrile/water was used for extraction. Every extraction step was controlled by tracer experiments. Briefly, the frozen tissue was extracted in acetonitrile/H 2O (1/1 (v/v), 10 ml/g tissue), and heated for 10 min at 70ЊC in a water bath to prevent proteolytic interference during radioimmunoassay (RIA) incubation. Aliquots of 2 ml were then centrifuged at 22,000 1 g for 15 min at room temperature. The supernatants were collected and the procedure was repeated with a 0.5 ml solvent/probe. The combined supernatants from each aliquot were evaporated in a vacuum and treated with pentane (1 ml/ sample) to remove the fat. The desiccated skin extracts were stored at 070ЊC until use for RIA or reversed-phase high performance liquid chromatography (RP-HPLC). The extraction method described and the RIA used for h/r/mCRF allowed the separation and determination of CRF in mouse skin in femtomolar amounts with satisfactory recovery (66%) (see below).
Extraction protocol #2
Skin was homogenized on ice in 0.5% Triton X-100 in phosphate-buffed saline, pH 7.4, containing 1 mM phenylmethylsulfonyl fluoride and 0.01% aprotinin (Sigma), as previously described (15, 21) . The extracts were centrifuged at 16,000 1 g for 30 min at 4ЊC. The supernatants were collected and purified through SEPCOL-1 containing 200 mg of C18, according to the manufacturer's protocol (Cat No. RIK-SEPCOL1, Penninsula, California) (25) . The purified peptide-containing fractions were stored at 070ЊC until use.
Extraction protocol #3
Plasma (1 ml) was extracted in 1 ml acetonitrile/H 2 0 (1/1 (v/ v), containing 0.1% trifluoroacetic acid (TFA)/0.01% Triton X-100), and heated for 10 min at 95ЊC in a water bath. After centrifugation at 22,000 1 g for 15 min at room temperature, the supernatant was collected and the procedure was repeated with a 0.5 ml solvent. The combined supernatants were evaporated in a vacuum and stored at 070ЊC until use.
Radioimmunoassay
Immediately before RIA (26), the acid-extracted skin fractions were resuspended in 300 ml 0.066 M phosphate buffer, pH 7.4, containing 0.12 M NaCl, 0.1% NaN 3 , 0.1% BSA, and 0.1% Triton X-100 (RIA buffer), sonicated for 7 min, incubated at 4ЊC for 1 h, and centrifuged at 22,000 1 g for 15 min at 4ЊC. The pellets were resuspended in 225 ml of RIA buffer and treated as described above. Both supernatants were combined and used for RIAs. Standard hCRF in the range of 0.3-52 / 3822 0014 Mp 289 Wednesday Jan 21 11:07 AM LP-FASEB 0014 fmol/tube or reconstituted skin extracts were preincubated with antiserum RII (100 ml, 1:30,000) for 20 h at 4ЊC (final volume 500 ml). Then 100 ml of hCRF tracer (7,000-10,000 cpm) was added, followed by incubation for 48 h at 4ЊC. To separate the free and antibody-bound tracer fraction, 250 ml of the suspension of a solid phase-bound sheep anti-rabbit antibody was added and the mixture was incubated for 45 min at 4ЊC. After centrifugation (42001g, 10 min, 4ЊC), the supernatants were aspirated. The radioactivity of the bound tracer in the sediment was counted in a Gamma Counter 1470 Wallac Wizard (Wallac Oy, Turku, Finland).
The rabbit antiserum RII used was directed toward the carboxyl-terminal sequence of hCRF and cross-reacted with hCRF(Ox), hCRF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , the related peptide urocortin, the peptide hormones somatostatin, thyrotropin-releasing hormone, growth hormone-releasing factor, luteinizing hormone-releasing hormone, substance P, Leu-enkephalin, Met-enkephalin, human b-endorphin, b-casomorphin, angiotensin I, human growth hormone, thyroidstimulating hormone, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotropin, ACTH, a-MSH, and b-lipotropic hormone (24, 26) . Tracer (50-60%) was bound by the antiserum RII in a final dilution of 1:180,000.
The detection limit was 0.6 fmol hCRF per tube, and the 50% intercept was at 5.6 fmol/tube. The intra-assay coefficients of variation at 2.9, 5.4, 9.0, and 18.9 fmol hCRF/tube were 5.6, 3.3, 3.5, and 3.6%, respectively, and the corresponding interassay coefficients of variation were 9.9, 8.8, 7.7, and 6.7%, respectively. Parallelism was demonstrated between the standard curve and dilution curves of CRF-IR-containing tissue extracts.
In some experiments (monitoring of the RP-HPLC separated fractions for CRF) we used a commercially available RIA kit (25) from Advanced ChemTech (Louisville, Ky.; cat# JRR2171). The assays were done according to the manufacturer's protocol. The minimum detectable sensitivity of the CRF was 2.7 fmol/tube. The cross-reactivity of the CRF antibody with CRF from human/rat was 100%; with bovine or ovine, it was 0.1%. The antibody did not cross-react with preproCRF 125-151 (human), urocortin (rat), urotensin I (catostomus commersoni), ACTH, [Arg 8 ]-vasopressin, or BNP-45 (rat). The intra-and interassay variation coefficients were below 4.9% and 12.7%, respectively.
Quantitative CRF receptor autoradiography
Cryosections of C57BL/6 back skin were prepared as described (19) . As positive controls, pituitary glands from male Wistar rats were isolated and treated in the same way as the mouse skin. Sections of skin (10 mm) were cut using a cryostat microtome, thaw-mounted on aminosilan-coated slides, and stored at 080ЊC until use. On the day of assay, slides were brought to room temperature, preincubated for 15 min at room temperature in 50 mM Tris/HCl (pH 7.2), 10 mM MgCl 2 , 2 mM EGTA, 0.15 mM bacitracin, 0.0015% aprotinin, and 0.1% BSA (assay buffer), and washed twice for 30 s in the same buffer. Sections were then incubated in assay buffer with 0.1 nM 125 I-[Tyr 0 ]-oCRF in the absence and presence of different concentrations (0.1 nM up to 1 mM) oCRF at 25ЊC for 2 h. Nonspecific tracer binding was determined in the presence of 1 mM oCRF. At the end of incubation, the slides were consecutively washed four times for 30 s in ice-cold assay buffer (without bacitracin, aprotinin, or BSA) containing 0.01% Triton X-100, dipped twice in deionized water, and dried rapidly under a constant stream of cold air. Slides were then apposed together with a 125 I-labeled standard (autoradiographic 125 I microscales, Amersham International, Buckinghamshire, England) to imaging plates (BAS-UR, Fuji Photo Film Co., Ltd, Tokyo, Japan) for 18 h.
Autoradiograms from the imaging plates were generated using the bioimaging analyses system BAS 3000 (Fuji Photo Film Co., Ltd, Tokyo, Japan) and quantified with the image analysis system MCID (Imaging Research Inc., St. Catharines, Ontario, Canada). The optical density of each labeled skin section was measured and converted to desintegrations per min/mg tissue equivalent, using a standard curve generated by 125 I-labeled standards. Receptor affinity (K d Å1/K ass ) was estimated according to the nonlinear least squares curve fitting program RADLIG (Biosoft, Cambridge, England).
After imaging plate autoradiography, the slides were dipped in Ilford Nuclear Research emulsion L4, dried at room temperature for 2 h, and stored for 2 wk with desiccant at 4ЊC in order to determine the localization of tracer binding at light microscopic level. Then the autoradiograms were developed (Kodak D 19 (1:1)), and the sections were stained with hematoxylin and eosin.
Reverse-phase high performance liquid chromatography
Skin extracted with acetonitrile (heating as in protocol #1) and peptide preparations obtained by purification of detergent-extracted skin throughout SEPCOL-1 (protocol #2) were each independently subjected to RP-HLPC. The extracts were separated by RP-HPLC on a Jasco gradient HPLC system (two 980 pumps; Jasco GmbH, Germany), using a PolyEncap A300 column (25014.6 mm i.d., 5 mm; Bischoff Analysentechnik GmbH, Leonberg, Germany). The sample was dissolved in 0.1% TFA in 5% acetonitrile/95% water containing 0.01% Triton X-100, centrifuged in microfuge, and supernatants were used for injection; the injection volume was 200 ml. Mobile phase A was 0.1% TFA in water and phase B was 0.1% TFA in 80% acetonitrile/20% water (v/v). Separations were performed at a flow rate of 1 ml/min at ambient temperature, using a linear gradient 5-95% B for 40 min. Fractions of the eluent were collected with a GradiFrac (Pharmacia Biotech, Uppsala, Sweden) at 1 min intervals in polypropylen tubes and subsequently evaporated in a Speed Vac concentrator (Alpha 2-4, Christ, Osterode, Germany). After reconstitution in the buffer, fractions were monitored for CRF by the RIA assay described above.
The peptides purified by SEPCOL-1 (C18 resin, 200 mg) were dissolved in HPLC grade water containing 0.1% TFA and injected (100 ml) into a Beckman Ultrasphere C18 IP HPLC column (15014.6 mm, 5 mm particle size) (25) . An ISCO Dual Pump Model 2350 HPLC system with an ISCO V 4 variable wavelength UV detector was used to separate the peptides. The flow rate was 1 ml/min, and 1 min fractions were collected. A linear gradient of 20 to 47% acetonitrile in 0.1% TFA over a period of 45 min was used to elute neuropeptides (25) . The elution time had been standardized with synthetic h/rCRF peptide. The eluted fractions were lyophilized; after reconstruction in the buffer, they were assayed with the use of a CRF RIA kit (Advanced ChemTech, Louisville, Ky.) according to the manufacturer's protocol.
Reverse transcriptase-polymerase chain reaction (RT-PCR) assays
Synthesis of the cDNA from 0.5 mg of poly (A) / mRNA or 2 mg of total isolated from skin, brain, and pituitary was performed as previously described (11) . The 581 kb fragment derived from the coding region of the murine CRF exon 1-2 was amplified as previously described (11, 27) 
94ЊC, 1 min at 60ЊC, and 2 min at 72ЊC, with a final extension of 7 min at 72ЊC. PCR reaction contained 11 PCR buffer Perkin Elmer (2.5 mM MgCl2), 500 nM of the primers, 250 nM of dNTPs, and 1U of Amplitaq (Perkin Elmer). As a negative control, RNA samples that were not reverse transcribed were run in parallel. The reverse transcribed pituitary and brain were used as positive controls. The PCR products were separated electrophoretically on 1.5% agarose gels, stained with ethidium bromide, and photographed under UV.
To confirm specificity, the products of RT-PCR were transfered to nylon membranes (Oncor, Gaithersburg, Md.) and hybridized with the 32 P-labeled murine CRF cDNA (gift of Dr. J. Majzub, Children's Hospital, Boston, Mass.), as previously described (11, 27) .
Immunohistochemistry
Immunohistochemical detection of CRF and CRF-R1 was carried out using rabbit antiserum against CRF (Euro-Diagnostica AB, Malmo, Sweden or Penninsula Lab, Calif.) and goat antiserum against an epitope corresponding to amino acids 425-444 mapping at the carboxyl terminus of the CRF-R1 precursor (Santa Cruz Biotechnology, Santa Cruz, Calif.), following protocols previously described (28, 29) . Acetonefixed cryostat sections were used for the analysis of CRF and CRF-R1 distribution in C57BL/6 mouse skin.
Sections fixed for 10 min at 020ЊC in acetone were incubated with anti-CRF and anti-CRF-R1 antibodies (dilution 1:50 and 1:100, respectively) overnight at room temperature, followed by incubation with tetramethylrhodamine-isothiocyanate-conjugated F(ab) 2 fragments of a goat anti-rabbit IgG (1:200 dilution, 1 h, 37ЊC) (Jackson ImmunoResearch Inc., West Grove, Pa.) or with biotinylated swine anti-goat IgG (1:200 dilution, 1 h, room temperature) (Cedarlane, Hornby, Canada), respectively. In the former case, the immunodistribution of CRF antigen was analyzed by fluorescence microscopy. In the latter, the CRF-R1 binding immunocomplexes were detected by using a streptavidine-alkaline phosphatase (1:500) amplification kit and examined by light microscopy.
Each immunoreactivity pattern was analyzed in at least 20 hair follicles per mouse, using at least five mice per hair cycle stage, and was recorded in a standarized, computer-generated scheme of the murine hair cycle (30) . Preincubation of antiserum against CRF with 50 mg/ml of CRF peptide (Sigma St. Louis, Mo., or Penninsula, Calif.) or incubation with nonimmune serum was used as a negative control. Immunohistochemical detection of both antigens in embryonic mouse brain was used as a positive control. The micrographs were prepared using the digital image analysis system ISIS (29, 30) .
RESULTS
Hair cycle-dependent CRF peptide expression in mouse skin
To identify CRF peptide in adolescent C57BL/6 back skin homogenates, we used two independent extraction protocols: an extraction with acetonitrile/water, and a detergent extraction technique with subsequent SEPCOL-1 purification. Both extracts were analyzed independently by RP-HPLC, and the collected fractions were tested using specific anti-CRF RIA. Using the former extraction protocol, we have identified the major CRF-like IR eluting at the same time as synthetic CRF standard (25 min), preceded by a minor peak eluting at 22 min that corresponded to the elution time of CRF(Ox) (Fig. 1) .
The presence of CRF in murine skin was fully confirmed by independent RP-HPLC separations of SEP-COL-1-purified anagen III-IV and VI skin extracts and identification of CRF-IR with a commercially available CRH RIA kit (Fig. 2) . Again, we detected a major CRF-IR eluting at the same time as CRF standard, 31 min (Fig. 2) . No specific IR was detected by anti-CRF antibody in these extracts at elution times that corresponded to urocortin, urotensin, and sauvagine peptides either in combined anagen III-IV (Fig. 2) or anagen VI skin.
The concentration of CRF immunoreactive peptide was measured in mouse skin of full thickness during all key phases of the murine hair cycle (Fig. 3) . The highest CRF-IR concentrations were seen at day 5 (anagen IV) after hair depilation with 67 fmol/g wet weight tissue of skin, which significantly decreased on day 10 (anagen VI) to a level of 40 fmol/g and then reached the lowest values (36 fmol/g) in telogen skin. There were statistically significant differences between days 3 and 5, as well as between days 3 and 5 and all other days, including day 0 (telogen), when using the Student-Newman-Keuls-test (Põ0.05).
In addition, CRF concentration in plasma was determined in telogen and anagen IV skin; their values were 5.6 and 8.6 fmol/ml plasma, respectively. For comparison, CRF concentrations reported in rat plasma were determined to be 2.0-2.8 fmol/ml (31, 32) . The CRF-IR was detected at the same elution time as CRF standard by RP-HPLC (not shown). Because cutaneous CRF levels (Fig. 3) are substantially higher than CRF plasma levels, the hair cycle-dependent changes in CRF skin levels are unlikely to reflect CRF plasma changes.
Using RT-PCR, we had previously failed to detect the CRF mRNA spanning exon 1-2 region in telogen, anagen, and catagen C57BL/6 mouse skin (11) . Despite an increased number of PCR cycles (up to 45) with subsequent Southern blotting, we again failed to detect a specific fragment that would hybridize with CRF cDNA prepared from mouse skin, despite its presence in the positive control mouse brain (not shown).
Identification and characterization of CRF receptors in mouse skin
Specific CRF binding sites (autoradiographic grains) were detected by autoradiography in murine skin labeled with 125 I-TyrЊ-oCRF (Fig. 4) . Specific and identifiable binding sites were present in the panniculus carnosus (i.e., the subcutaneous muscle layer of rodent skin), hair follicle, and epidermis. The highest concentration of CRF binding sites was detected in the panniculus carnosus (Fig. 4) .
The CRF binding sites in mouse skin were determined with quantitative autoradiography by a competitive displacement assay in skin sections obtained from mice in the telogen stage. The competitive displacement of the binding of 
In situ localization of CRF and CRF-R1 antigens
Immunofluorescence studies showed hair cycle-dependent changes in the distribution of CRF-IR and CRF-R1 protein in mouse skin (Fig. 6 and Fig. 7) . Large nerve bundles in the dermis and subcutis displayed CRF-IR throughout the hair cycle (Fig. 6A) . In telogen and anagen II skin, CRF-IR was localized mainly in basal layer epidermal keratinocytes and in keratinocytes of the suprainfundibular outer root sheath, as well as in keratinocytes of the bulge and the developing anagen hair bulb (Fig. 6A and Fig. 7) . In anagen IV, CRF-IR was present in most keratinocytes of the epidermis and of the proximal outer root sheath (Fig. 6C and Fig. 7) . CRF-IR also appeared in longitudinal and circular nerve fibers around the hair follicle isthmus (Fig. 6C and Fig. 7) , i.e., in the so-called follicular neural network B (FNB) (29) . Anagen VI hair follicles displayed CRF-IR in the proximal outer/inner root sheath and hair matrix as well as in nerve fibers of the FNB (Fig. 6E and Fig.  7) . In catagen, CRF-IR was present in the secondary hair germ, proximal outer root sheath, and nerves around the isthmus, and disappeared in the epider- mis, inner root sheath, and distal outer root sheath ( Fig. 6G and Fig. 7) . CRF-R1-IR was at the level of background in telogen skin (Fig. 6B and Fig. 7) , whereas identifiable CRH-R1-IR began to appear in germ plate keratinocytes of the developing hair bulb of anagen II follicles. Numerous keratinocytes of the proximal inner root sheath and some keratinocytes of the proximal outer root sheath also displayed CRF-R1-IR during anagen IV (Fig. 6D and Fig. 7) . In anagen VI, CRF-R1-IR appeared in dermal papilla fibroblasts, was present in the proximal outer and inner root sheath, but disappeared from the hair matrix (Fig. 6F  and Fig. 7) . In catagen, CRF-R1-IR was present only in keratinocytes of the regressing inner root sheath (Fig. 6H and Fig. 7 ).
DISCUSSION
We demonstrate the presence of both CRF and CRF-R antigens in C57BL/6 mouse skin. RP-HPLC and RIA analyses of skin extracts from different hair cycle stages documented the presence of CRF peptide in the skin. The amount of CRF changed with synchronized hair follicle cycling, peaking in anagen IV skin. This correlated well with the maximal CRF expression identified by immunofluorescence in anagen skin. Maximal CRF-IR was localized to the basal epidermis, the outer root sheath, and matrix region of anagen IV-VI follicles and their neural network B, whereas minimal CRF-IR was detected in catagen and telogen skin.
A question remains as to what the source of intracutaneous CRF may be. The discrepancy between the presence of peptide and an apparent absence of CRF gene expression in murine skin suggests that the identified CRF-IR may originate from an extracutaneous site of synthesis. It may be delivered to skin via descending nerve endings, as proposed previously (11) . This possibility appears to be supported by the presence of CRF-IR in nerve bundles of dermis/subcutis and by positive CRF staining of longitudinal and circular FNB nerve fibers (see Fig. 6 and Fig. 7) . Some CRF may also derive from the serum, but this is an unlikely possibility because plasma levels of CRF are substantially lower than the concentration of CRF in skin. The observed strong intraepithelial CRF-IR stain may then represent predominantly receptormediated internalization of CRF released by nerve endings. Because human skin expresses CRF, CRF-R1 mRNA (10) , and CRF peptide (25) , it is also possible that part of the detected CRF-IR is the product of an as yet unidentified cutaneous gene whose product shows high homology to hypothalamic CRF.
Since CRF is the major regulator of pituitary POMC gene expression and production of POMC peptides (1, 2) , it is conceivable that the increased content of CRF in anagen IV is functionally linked to synthesis of the POMC protein, with subsequent pro- duction of POMC peptides such as ACTH, MSH, and b-endorphin. There is indeed hair cycle-dependent expression of POMC mRNA, protein, and POMC-derived b-endorphin in the skin of C57BL/6 mice (11, 20, 22) .
Specifically, a 30 to 33 kDa POMC protein was detected in anagen IV, but not in telogen or anagen I-III skin; full-length POMC mRNA of 1.1 kb was detected only in anagen IV; truncated POMC transcripts of 0.9 kb were detected in other phases of the ]-oCRF bound to sections of mouse skin (᭺) and sections of rat pituCRF-R type 1 CRF-R type 1 itary (l). The displacement curves resulted from multifile analysis (RADLIG) of two independent binding experiments, each using six skin sections/ concentration, and of three independent experiments, each using two sections of rat pituitary/concentration. hair cycle (11, 20, 27) . The progression through the hair cycle was accompanied by an increased concentration of POMC-derived b-endorphin, reaching a peak in anagen VI (22) . Further support for the hypothesis that intracutaneous CRF expression may, at least in part, control local POMC (12) comes from an in situ hybridization study showing that POMC mRNA is expressed in epidermal and outer root sheath keratinocytes during anagen (33)-in those cells that displayed strong CRF-IR during anagen development.
By quantitative autoradiography, we have presented the first evidence that mammalian skin expresses high-affinity binding sites for CRF, with the highest density of specific binding sites in the panniculus carnosus, epidermis, and follicle epithelium. The high-affinity binding sites for CRF had a K d of 3.62 nM, which is comparable to that of rat pituitary (1.53 nM) and brain (4.31 nM) (34) . However, the concentration of binding sites in skin (B max of 2.42 amol/mm 2 ) was much lower than that in the pituitary (18.1 amol/mm 2 ). Although this study is in general agreement with previous detection of the CRF-R1 mRNA in mouse skin (11) and the in situ localization of the CRF-R1 antigen to the hair follicle presented here, some peculiarities need to be considered.
Previously, we had detected hair cycle-dependent steady-state levels of CRF-R1 mRNA, with a maximum in anagen VI and a minimum in telogen (11) . Here we show by immunohistology that the distribution of CRF-R1 antigens also changes in a hair cycle-dependent manner, since CRF-R1 immunoreactivity was absent in telogen skin and reached its highest value in anagen VI (Fig. 6 and Fig. 7) . In contrast, autoradiography did not reveal striking differences in total CRF binding between telogen and anagen skin. In addition, CRF-R1 immunoreactivity in situ was located predominantly in the epithelial structures of anagen and catagen hair follicles and in the dermal papilla of anagen VI follicles, but not in the epidermis or panniculus carnosus.
This raises the question of whether, in addition to CRF-R1, other CRF receptors are expressed in murine skin. The CRF-R gene family includes at least two genes that share high sequence homology and belong to the seven-transmembrane receptor protein family coupled to the Gs signaling protein (6) (7) (8) (9) . CRF-R1 is expressed preferentially in the brain and pituitary gland, and CRF-R2b is expressed in heart and skeletal muscle (6) (7) (8) (9) . In preliminary studies, we have amplified (by using RT-PCR) an expected 775 bp fragment from the coding region of the CRF-R2 gene in mouse skin and brain. Thus, it is conceivable that mouse skin expresses more than one CRF-R gene and that the CRF-R2 gene might be expressed predominantly in the panniculus carnosus and epidermis, whereas CRF-R1 expression may predominate in the hair follicle.
The hair follicle and its cyclic growth and regression activity offer an ideal model system for studying developmentally controlled epithelial-mesenchymal-neuroectodermal interaction systems (cf. refs 14, 16, 35) . Therefore, the current observations on hair cycle-dependent expression of CRF and CRF receptors in murine skin in an exceptionally well-defined and easily manipulated mouse model raise intriguing developmental questions as to the role of CRF/CRF-R-dependent signaling in the control of epithelialmesenchymalneuroectodermal interactions in general, and in the control of epithelial tissue remodeling during morphogenesis and postnatal tissue homeostasis in particular (cf. refs 36, 37). It will now be critical to explore, for example, whether CRF-R agonists and antagonists interfere with hair follicle cycling in a manner that might be exploited therapeutically (cf. refs 14, 16) , or that may provide further proof for the hypothesis that the tissue remodeling of peripheral organs can indeed be affected by interaction with the receptors for 'hypothalamic' hormones (4, 12) . In addition, CRF-overproducing transgenic mice (38) and CRF-deficient knockout mice (39) that have recently become available offer instructive complementary tools for dissecting in detail how over-or understimulation of CRF receptors can affect hair follicle morphogenesis, growth, and cycling.
In conclusion, we suggest that the CRF-CRF receptor signaling system is operating in mouse skin as an additional 'neuroendocrine' pathway that regulates 
